Prelude Therapeutics Incorporated

NasdaqGS:PRLD Stock Report

Market Cap: US$69.9m

Prelude Therapeutics Valuation

Is PRLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRLD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRLD's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRLD?

Other financial metrics that can be useful for relative valuation.

PRLD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does PRLD's PS Ratio compare to its peers?

The above table shows the PS ratio for PRLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19x
XLO Xilio Therapeutics
19.4x7.3%US$56.7m
CNTB Connect Biopharma Holdings
2.6x14.3%US$65.5m
IVVD Invivyd
52.8x47.9%US$124.2m
BLUE bluebird bio
1.3x38.0%US$85.2m
PRLD Prelude Therapeutics
23.3x9.4%US$69.9m

Price-To-Sales vs Peers: PRLD is expensive based on its Price-To-Sales Ratio (23.3x) compared to the peer average (19x).


Price to Earnings Ratio vs Industry

How does PRLD's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.0%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.0%
n/an/an/a
No more companies

Price-To-Sales vs Industry: PRLD is expensive based on its Price-To-Sales Ratio (23.3x) compared to the US Biotechs industry average (12.2x).


Price to Sales Ratio vs Fair Ratio

What is PRLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRLD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23.3x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: PRLD is expensive based on its Price-To-Sales Ratio (23.3x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRLD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.27
US$6.50
+411.8%
35.3%US$10.00US$4.00n/a4
Nov ’25US$1.24
US$5.40
+335.5%
55.7%US$10.00US$1.00n/a5
Oct ’25US$2.03
US$5.80
+185.7%
42.8%US$10.00US$3.00n/a5
Sep ’25US$5.20
US$5.80
+11.5%
42.8%US$10.00US$3.00n/a5
Aug ’25US$5.65
US$4.75
-15.9%
31.1%US$7.00US$3.00n/a4
Jul ’25US$3.77
US$4.75
+26.0%
31.1%US$7.00US$3.00n/a4
Jun ’25US$3.85
US$4.75
+23.4%
31.1%US$7.00US$3.00n/a4
May ’25US$3.73
US$4.75
+27.3%
31.1%US$7.00US$3.00n/a4
Apr ’25US$4.69
US$4.75
+1.3%
31.1%US$7.00US$3.00n/a4
Mar ’25US$4.59
US$4.00
-12.9%
20.4%US$5.00US$3.00n/a3
Feb ’25US$3.27
US$4.50
+37.6%
11.1%US$5.00US$4.00n/a2
Jan ’25US$4.27
US$4.00
-6.3%
20.4%US$5.00US$3.00n/a3
Dec ’24US$3.23
US$6.00
+86.0%
49.1%US$10.00US$3.00n/a3
Nov ’24US$1.86
US$7.75
+316.7%
29.4%US$10.00US$5.00US$1.244
Oct ’24US$3.09
US$10.50
+239.8%
40.7%US$17.00US$5.00US$2.034
Sep ’24US$3.66
US$9.40
+156.8%
46.9%US$17.00US$5.00US$5.205
Aug ’24US$3.69
US$10.00
+171.0%
38.5%US$17.00US$6.00US$5.655
Jul ’24US$4.50
US$10.00
+122.2%
38.5%US$17.00US$6.00US$3.775
Jun ’24US$5.56
US$10.00
+79.9%
38.5%US$17.00US$6.00US$3.855
May ’24US$6.16
US$10.00
+62.3%
38.5%US$17.00US$6.00US$3.735
Apr ’24US$5.70
US$10.00
+75.4%
38.5%US$17.00US$6.00US$4.695
Mar ’24US$5.93
US$9.60
+61.9%
32.7%US$15.00US$6.00US$4.595
Feb ’24US$6.59
US$9.60
+45.7%
32.7%US$15.00US$6.00US$3.275
Jan ’24US$6.04
US$9.60
+58.9%
32.7%US$15.00US$6.00US$4.275
Dec ’23US$6.61
US$9.60
+45.2%
32.7%US$15.00US$6.00US$3.235
Nov ’23US$6.65
US$10.20
+53.4%
31.2%US$16.00US$7.00US$1.865

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies